Abstract
Over the years, the design of HSV-1 based vectors has developed from different types of replicative-defective and replication-conditioned recombinant viruses to plasmid based amplicon vectors. More recently hybrid or chimeric vectors have incorporated desired elements of different viruses to increase the efficacy of gene delivery in vitro and in vivo. Amongst different systems, herpesvirus / retrovirus chimeras take advantage of the features of the HSV-1 vectors to efficiently transduce large amounts of foreign genetic sequences, remaining episomal, to allow production of recombinant retrovirus vectors able to stably integrate into the cellular genome. This review will focus on three different groups of herpesvirus / retrovirus chimeric vectors aimed to; generate retrovirus particles in cells tranduced with HSV-1 amplicon vectors; express a limited set of retrovirus genes for vaccine purposes; and express herpesvirus / retrovirus chimeric proteins to study cellular targeting signal and improve their biological effect.
Keywords: herpes simplex virus type 1, retrovirus, chimeric vectors, retrovirus-like particles, chimeric proteins
Current Gene Therapy
Title: Herpesvirus / Retrovirus Chimeric Vectors
Volume: 4 Issue: 4
Author(s): Alberto L. Epstein and Roberto Manservigi
Affiliation:
Keywords: herpes simplex virus type 1, retrovirus, chimeric vectors, retrovirus-like particles, chimeric proteins
Abstract: Over the years, the design of HSV-1 based vectors has developed from different types of replicative-defective and replication-conditioned recombinant viruses to plasmid based amplicon vectors. More recently hybrid or chimeric vectors have incorporated desired elements of different viruses to increase the efficacy of gene delivery in vitro and in vivo. Amongst different systems, herpesvirus / retrovirus chimeras take advantage of the features of the HSV-1 vectors to efficiently transduce large amounts of foreign genetic sequences, remaining episomal, to allow production of recombinant retrovirus vectors able to stably integrate into the cellular genome. This review will focus on three different groups of herpesvirus / retrovirus chimeric vectors aimed to; generate retrovirus particles in cells tranduced with HSV-1 amplicon vectors; express a limited set of retrovirus genes for vaccine purposes; and express herpesvirus / retrovirus chimeric proteins to study cellular targeting signal and improve their biological effect.
Export Options
About this article
Cite this article as:
Epstein L. Alberto and Manservigi Roberto, Herpesvirus / Retrovirus Chimeric Vectors, Current Gene Therapy 2004; 4 (4) . https://dx.doi.org/10.2174/1566523043345922
DOI https://dx.doi.org/10.2174/1566523043345922 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents The Application of Nanomaterials in Stem Cell Therapy for Some Neurological Diseases
Current Drug Targets The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
Current Medicinal Chemistry Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design